Analysts Review of Stock: Exact Sciences Corporation (EXAS)

Marco Green
April 29, 2018

EXACT Sciences has a 12-month low of $29.45 and a 12-month high of $63.60.

The stock increased 2.94% or $1.33 during the last trading session, reaching $46.6. About 7.36 million shares traded or 191.61% up from the average.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Thursday, April 26th. It has outperformed by 69.88% the S&P500.

Sentry Select Capital Corp decreased its stake in Cisco Systems Inc (CSCO) by 8.19% based on its latest 2017Q4 regulatory filing with the SEC.

The short ratio in the company's stock is documented at 5.58 and the short float is around of 11.97%. The institutional investor held 21,756 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $1.24M, up from 14,666 at the end of the previous reported quarter. This particular public company has given a ROE of 6.20%. The stock decreased 0.14% or $0.03 during the last trading session, reaching $20.86. About 4.14M shares traded. KKR & Co. L.P. (NYSE:KKR) has risen 15.21% since April 28, 2017 and is uptrending. It has outperformed by 14.02% the S&P500. Therefore 75% are positive. Benchmark maintained the stock with "Buy" rating in Tuesday, October 31 report. The stock has "Buy" rating by Leerink Swann on Monday, November 13. One can easily calculate and measure stock using moving average charts, diagrams and commanding visual trend-spotting tool. The firm earned "Hold" rating on Tuesday, November 24 by Lake Street. The stock deteriorated -7.28% during the past three month period and discounted -6.03% in half year.

Since January 2, 2018, it had 0 buys, and 20 selling transactions for $24.73 million activity. $87,474 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by COWARD D SCOTT. 14,550 shares were sold by LIDGARD GRAHAM PETER, worth $756,271 on Friday, March 9. Doyle James Edward had sold 3,098 shares worth $126,925.

During 2017 Q4 the big money sentiment decreased to 0.88. Its down 0.13, from 1.01 in 2017Q3. It is positive, as 51 investors sold CSCO shares while 660 reduced holdings. Operating profit margin is positioned at -44.50%. Wasatch holds 0.89% or 1.27 million shares in its portfolio. Nicholas Partners LP invested 0.72% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). Winch Advisory Services Limited Liability holds 0% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS) for 19 shares. ValuEngine raised shares of EXACT Sciences from a "hold" rating to a "buy" rating in a research report on Monday, April 2nd. Central Bank & Trust Trust reported 17,149 shares.

Exact Sciences Corporation (NASDAQ:EXAS) now has a PEG ratio of N/A where as its P/E ratio is N/A. The rating was maintained by Craig Hallum on Wednesday, July 26 with "Buy". 208,070 were accumulated by Granahan Invest Inc Ma. Spark Invest Mngmt Ltd Liability Com reported 0.1% in Exact Sciences Corporation (NASDAQ:EXAS). Southport Llc invested in 9,000 shares. Moors And Cabot Inc, a Massachusetts-based fund reported 4,501 shares. Fisher Asset Management Ltd has 6,350 shares. Neuberger Berman Group Limited holds 0% or 18,173 shares in its portfolio. $243,068 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by ARORA MANEESH.

Investors sentiment increased to 0.91 in Q4 2017. 123 funds opened positions while 430 raised stakes. Citadel Advisors Ltd Liability Corporation stated it has 147,976 shares or 0% of all its holdings. Summit Grp Lc has 323,500 shares. 56,575 are held by Ledyard Bancorp. 850.39 million shares or 3.82% less from 884.13 million shares in 2017Q3 were reported. Royal Comml Bank Of Canada holds 42,684 shares or 0% of its portfolio. Ibm Retirement Fund has 0.44% invested in Abbott Laboratories (NYSE:ABT). Axa owns 131,500 shares.

Sentry Select Capital Corp, which manages about $7.87 billion US Long portfolio, upped its stake in Crown Holdings Inc (NYSE:CCK) by 53,400 shares to 1.39 million shares, valued at $78.31 million in 2017Q4, according to the filing. It was reported on April, 28 by Tci Wealth Advsrs invested in 68 shares or 0% of the stock. Palladium Prns Limited Liability Company accumulated 28,108 shares. Shares for $1.07 million were sold by Conroy Kevin T on Friday, February 23. 11,106 Abbott Laboratories (NYSE:ABT) shares with value of $667,804 were sold by Fussell Stephen R. Another trade for 996 shares valued at $58,635 was made by Watkin Jared on Wednesday, February 28. The insider Carey Thomas D. sold 8,448 shares worth $335,630. Also, Director Katherine S. Zanotti sold 7,232 shares of the stock in a transaction on Thursday, April 12th. (1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Abbott Laboratories had 107 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has "Overweight" rating given on Friday, February 12 by Barclays Capital. The quarterly total beat the company's projection in February that it would complete between 176,000 and 181,000 of the tests in the first quarter. The rating was maintained by Leerink Swann on Wednesday, March 28 with "Buy". (NASDAQ:SIRI) rating on Friday, September 30. BMO Capital Markets maintained it with "Market Perform" rating and $5 target in Thursday, October 19 report. Pivotal Research has "Buy" rating and $5.65 target. Canaccord Genuity has "Buy" rating and $26 target.

Other reports by Click Lancashire

Discuss This Article